Last reviewed · How we verify
Campath Purged Non-myeloablative ASCT
Campath (Alemtuzumab) is a monoclonal antibody that targets CD52, a protein found on the surface of mature lymphocytes.
Campath (Alemtuzumab) is a monoclonal antibody that targets CD52, a protein found on the surface of mature lymphocytes. Used for Chronic lymphocytic leukemia (CLL).
At a glance
| Generic name | Campath Purged Non-myeloablative ASCT |
|---|---|
| Also known as | Allogeneic Stem Cell Transplant (ASCT) |
| Sponsor | David Rizzieri, MD |
| Drug class | Monoclonal antibody |
| Target | CD52 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Alemtuzumab binds to CD52, leading to the depletion of mature lymphocytes, which can help reduce the immune system's attack on the body. This mechanism is often used in the treatment of autoimmune diseases and certain types of cancer.
Approved indications
- Chronic lymphocytic leukemia (CLL)
Common side effects
- Infusion reactions
- Infections
- Thrombocytopenia
Key clinical trials
- Allo Non-myeloablative SCT Utilizing Matched Family Member Stem Cells Purged Using Campath (PHASE2)
- Allo Non-Myeloablative SCT Utilizing Mis-Matched Family Member Stem Cells Purged Using Campath (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Campath Purged Non-myeloablative ASCT CI brief — competitive landscape report
- Campath Purged Non-myeloablative ASCT updates RSS · CI watch RSS
- David Rizzieri, MD portfolio CI